FDA Places Clinical Hold on Scynexis’ IV Antifungal, Lifts Hold on Seattle Genetics AML Treatment

The FDA has asked Scynexis to hold new clinical studies of an intravenous formulation of its antifungal treatment, SCY-078, until the agency can review available pre-clinical and clinical data.
Source: Drug Industry Daily